Ai-BrainScience

About Ai-BrainScience

Ai-BrainScience Inc. is a Japanese medical technology firm that emerged from research conducted at Osaka University. The company was formally established on November 13, 2019, to commercialize a novel method for cognitive assessment based on eye-tracking technology. This initiative was born out of a project supported by the Japan Science and Technology Agency (JST) starting in December 2018, which focused on developing a simple cognitive screening system using this technology. The President and CEO, Kentaro Takamura, who holds a Ph.D. in immunology and ophthalmology, has an extensive background in the healthcare industry, having held leadership roles at several medical and pharmaceutical companies before leading Ai-BrainScience.

The company's core business revolves around the development and distribution of medical device programs designed for the early detection of dementia. Its primary technology is the Eye Tracking-based Cognitive Assessment (ETCA), a method that analyzes a person's eye movements as they view a series of images and tasks on a tablet. This system provides a non-invasive, quantitative, and objective evaluation of cognitive functions such as memory, attention, and language in about three minutes. The firm addresses a significant challenge in healthcare, where a large percentage of dementia cases go undiagnosed due to the stressful and time-consuming nature of traditional tests.

Ai-BrainScience operates on a dual business model. The first pillar is the development of software as a medical device (SaMD) for clinical settings. The company collaborates with pharmaceutical firms for distribution, such as the exclusive sales agreement with Otsuka Pharmaceutical Co., Ltd. for its "AiBS-01" application in Japan. Revenue is generated through upfront payments, milestone fees, and royalties from these partnerships. The second pillar involves offering a version of its technology, the "MIRUDAKE" app, for general use, targeting corporate clients in sectors like long-term care and food services. The company is also developing next-generation devices that will incorporate AI and machine learning to analyze gaze plot data, aiming for more precise diagnostics to differentiate between various types of dementia, such as Alzheimer's disease and Lewy body dementia.